# OASIS 4 trial

Type: clinical trial

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/oasis-4-trial
Canonical HTML page: https://gethealthbrief.com/entity/oasis-4-trial

## Recent coverage (1 stories)

### First Daily GLP-1 Pill Approved: Wegovy Oral Achieves 17% Weight Loss in Trial
2026-06-11 16:43:14 · Sentiment: Bullish · Impact: 8/10 · Sources: 3

The MHRA’s landmark approval of oral semaglutide introduces a needle-free GLP-1 option for obesity, backed by a 17% weight-loss result in adherent patients. Healthcare providers must now navigate private-only access and patient education around strict dosing protocols.
Full story: https://gethealthbrief.com/story/wegovy-pill-uk-approval-oral-semaglutide-17-percent-weight-loss

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.